However, CD36 and Nox2 are expressed in many cells, including microglia, circulating myeloid cells, and endothelium, 28 and the relevant cell type(s) remain to be identified.
A lzheimer disease (AD) is the leading cause of cognitive impairment in the elderly, characterized pathologically by extracellular deposition of the amyloid-β peptide (Aβ) in amyloid plaques and intracellular aggregates of the microtubule-associated protein tau (neurofibrillary tangles). 1 Because of demographic shifts and lack of effective treatments, the prevalence of AD is estimated to rise to epidemic proportions in the next few decades, and disease-modifying therapeutic interventions are sorely needed. Several lines of evidence suggest that vascular factors play a pathogenic role in AD. 3, 4 Although vascular risk factors increase the risk of AD, [5] [6] [7] cerebrovascular function is altered in presymptomatic individuals who will develop AD, [8] [9] [10] suggesting an early involvement in the disease process. The brain is highly dependent on a continuous and well-regulated delivery of cerebral blood flow (CBF), and alterations in cerebral perfusion lead to brain dysfunction and cognitive impairment. [11] [12] [13] A large body of work indicates that Aβ disrupts key mechanisms regulating the cerebral microcirculation. [13] [14] [15] For example, Aβ suppresses the increase in CBF evoked by synaptic activity, a vital homeostatic response that matches oxygen and glucose delivery to the energy needs of the active brain, and disrupts endothelial function. [16] [17] [18] [19] [20] [21] These neurovascular alterations are mediated by the innate immunity receptor CD36 (cluster of differentiation 36), polymorphisms of which are linked to AD susceptibility. 22 CD36 binds Aβ and leads to NADPH oxidase 2 (Nox2)-dependent production of reactive oxygen species (ROS). [23] [24] [25] [26] [27] The perivascular space (Virchow-Robin space), limited by the glial basement membrane (glia limitans) and the vascular basement membrane, 29 has emerged as a major conduit for brain Aβ clearance, as well as a preferential site of Aβ accumulation. 30, 31 Brain Aβ, released extracellularly during synaptic activity, 32 reaches the perivascular space and exits the brain through different routes. 33 Brain perivascular macrophages (PVM), a unique population of brain myeloid cells distinct from macrophages in heart and systemic vessels, are closely apposed to the wall of cerebral resistance arteries in the perivascular space and, as all macrophages, can produce large amounts of ROS. [34] [35] [36] Therefore, PVM are exposed to Aβ and are uniquely poised to induce cerebrovascular oxidative stress, but their participation in the vascular effects of Aβ has not been explored.
We examined the role of PVM in the cerebrovascular actions of Aβ. We found that depletion of PVM abrogates the vascular oxidative stress and neurovascular dysfunction induced by Aβ, either administered to wild-type (WT) mice or produced endogenously in the brain of transgenic mice expressing a mutated form of APP (amyloid precursor protein; Tg2576 [mice overexpressing the Swedish mutation of the amyloid precursor protein {APPK670/671 L}]). Furthermore, using bone marrow (BM) chimeras, we demonstrated that expression of CD36 and Nox2 in PVM is absolutely required for vascular effects of Aβ. The findings implicate for the first time PVM in the neurovascular dysfunction of Aβ and suggest a novel mechanism by which brain-resident innate immune cells may promote AD.
Methods

Mice
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Weill Cornell Medicine. Experiments were performed in 3-to 4-month-old transgenic mice overexpressing the Swedish mutation of the APP (Tg2576) 37 or agematched WT littermates, referred to as WT mice. In BM chimera experiments, CD36
−/− and Nox2 −/− mice were used as BM donors. In some studies, GFP + mice (JAX Stock #006567) were used as BM donors. All mice were males and derived from in-house colonies.
23-26
Intracerebroventricular Injection of Clodronate or Dextran
Liposomes containing clodronate or PBS were administered intracerebroventricularly as previously described. 34, 38 Isofluraneanesthetized mice were placed in a stereotaxic frame. Ten microliters of clodronate liposomes (7 mg/mL) or PBS liposomes (vehicle) were injected into the cerebral ventricles with a glass micropipette through a burr hole drilled on the right parietal bone. Mice were used in the experiments 5 to 7 days later, when PVM depletion is well developed and stable. 34, 38 In some experiments, PVM were identified by their ability to phagocytize dextran. 34, 39 For dextran injections, 10 µL of Alexa Fluor 680 dextran (10 000 MW, anionic, fixable, ThermoFisher Scientific, D34680; 2.5 mg/mL) in saline or saline alone were injected, and PVM labeling was examined 24 hours later. 
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Novelty and Significance
What Is Known?
• Alzheimer disease, the most common cause of late-life dementia, is characterized pathologically by the accumulation in brain of the amyloid-β peptide (Aβ) and the microtubule-associated protein tau.
• Alterations in the regulation of the cerebral microcirculation have recently emerged as a significant contributor to cognitive impairment in Alzheimer disease.
• The neurovascular dysfunction is mediated by reactive oxygen species (produced by the binding of Aβ to the innate immunity receptor CD36 leading to activation of the superoxide-producing enzyme Nox2.
What New Information Does This Article Contribute?
• Perivascular macrophages (PVM), myeloid cells juxtaposed to the outer wall of arteriole penetrating the substance of the brain, are the main source of the reactive oxygen species mediating the neurovascular dysfunction produced by brain Aβ.
• PVM are also responsible for neurovascular alterations mediated by plasma Aβ, which crosses the blood-brain barrier and reaches these cells in the perivascular space.
• PVM are the cellular site of the expression of CD36 and Nox2 responsible for neurovascular dysfunction.
Alterations in the regulation of cerebral microvasculature play a pathogenic role in Alzheimer disease. Such neurovascular dysfunction may deprive the brain of oxygen and glucose, amplifying the harmful neuronal effects of Aβ and tau pathology. The Aβ peptide in brain and plasma alters neurovascular function through CD36-and Nox2-derived reactive oxygen species, but the cellular bases of the effect have not been elucidated. We report that brain PVM, a unique subpopulation of resident brain macrophages exposed to Aβ draining through the perivascular space, are necessary and sufficient for the oxidative stress driving the neurovascular dysfunction in mouse models of amyloid pathology. 40 Briefly, mice were anesthetized (5% isoflurane) and transcardially perfused with PBS (2 mL) followed by DiO (1:50, V-22886, Molecular Probes; 5 mL/mouse) and then by 4% paraformaldehyde. Brains were harvested and postfixed in 4% paraformaldehyde overnight and then cut (thickness 150 µm) using a vibratome and examined under the confocal microscope (Leica SP5).
Immunohistochemistry
Mice were anesthetized with sodium pentobarbital (120 mg/kg, IP) and perfused transcardially with PBS followed by 4% paraformaldehyde in PBS. Brains were removed, stored overnight, and sectioned in a vibratome (section thickness: 40 µm). Free-floating brain sections were permeabilized with 0.5% Triton X-100, and nonspecific binding was blocked with 1% of normal donkey serum. Sections were randomly selected and incubated with the primary antibodies CD206 (cluster of differentiation 206; clone MR5D3, rat polyclonal, 1:200; Serotec), Glut-1 (rabbit polyclonal, 1:200; Calbiochem), Iba-1 (rabbit polyclonal, 1:500; Wako Chemicals), or GFAP (glial fibrillary acidic protein; mouse monoclonal, 1:1000; Sigma) overnight at 4°C. After washing, brain sections were incubated with a cyanine 5-or a fluorescein isothiocyanate-conjugated secondary antibody (1:200; Jackson ImmunoResearch Laboratories), mounted on slides, and imaged with a confocal microscope (Leica SP5). The specificity of the immunofluorescence was verified by omission of the primary or secondary antibody or blocking of the antigen. All quantifications were performed by investigators blinded to the treatment on randomly selected fields within the somatosensory cortex.
Identification and Quantification of PVM in Somatosensory Cortex
PVM were identified by well-established criteria, including expression of CD206, ability to phagocytize dextran, and perivascular location 34, 38, 41 ( Figure 1 ). The association with cortical blood vessels was confirmed by colabeling with the endothelial marker Glut-1 (rabbit polyclonal, 1:200; Calbiochem), the smooth muscle marker α-actin, or DiO. 40 For CD206 + PVM, randomly selected fields (×20 objective; 4 confocal images/mouse; n=5 mice per group) within the somatosensory cortex were analyzed. For dextran + PVM, a representative coronal section from each mouse was reconstructed from tiled images taken with the confocal microscope, and the whole somatosensory cortex (n=3 per group) was analyzed. ImageJ (National Institutes of Health) was used for all image analyses.
Cerebrovascular ROS Measurement
ROS production was assessed in vivo by dihydroethidium microfluorography. [23] [24] [25] 34, 42 To assess ROS production in PVM, mice were first injected intracerebroventricularly with clodronate or PBS liposome and 5 to 7 days later with dextran (see above). The day after dextran injection, in WT mice dihydroethidium (2 µmol/L in Ringer; Invitrogen) with or without Aβ (5 µmol/L) was superfused over the somatosensory cortex. In tg2576 mice, dihydroethidium (10 mg/kg) was injected into the jugular vein. BM-transplanted mice were injected with intracerebroventricular dextran 1 day before ROS measurement. Sixty minutes after hydroethidine administration, mice were injected with DiO to label cerebral blood vessels as described above. Coronal brain sections were then cut through the cortex underlying the cranial window, and ROS-dependent fluorescence associated with blood vessels or PVM was quantified as described previously. [23] [24] [25] 34, 42 
BM Transplant
Procedures for BM transplant have been previously described 34, 43 and are only summarized. Whole-body irradiation was performed in 7-week-old mice (Nordion Gammacell 40 Exactor). Eighteen hours later, mice were transplanted with BM cells (2×10 6 , IV) isolated from the donor CD36
, and WT controls. Mice were housed in cages with sulfamethoxazole (0.12%; wt/vol) and trimethoprim (0.024%) added to drinking water for the first 2 weeks.
Reconstitution of BM cells was verified 5 weeks after irradiation by testing the percentage of positive CD36 or Nox2 genomic DNA in isolated blood leukocytes. 43 Chimerism was >95% for both CD36
−/− and Nox2 −/− BM chimeras. For studies of PVM number and distribution after BM transplant in Tg2576 mice, the BM of transgenic mice expressing GFP (green fluorescent protein) was transplanted into irradiated Tg2576 mice or littermates.
General Surgical Procedures for CBF Measurement
As described in detail elsewhere, 24, 25, 42 mice were anesthetized with isoflurane (induction, 5%; surgery, 2%) and maintained with urethane (750 mg/kg; IP) and α-chloralose (50 mg/kg; IP). A femoral artery was cannulated for recording of arterial pressure and collection of blood samples for blood gas analysis. The trachea was intubated, and mice were artificially ventilated with a mixture of N 2 and O 2 . Arterial blood pressure (80-90 mm Hg), blood gases (pO 2 , 120-140 mm Hg; pCO 2 , 30-40 mm Hg; pH, 7.3-7.4), and rectal temperature (37°C) were monitored and controlled. Throughout the experiment, the level of anesthesia was monitored by testing motor responses to tail pinch. The somatosensory cortex was exposed through a small craniotomy (2×2 mm). The dura was removed, and the exposed cortex was continuously bathed with a modified Ringer solution (36-37°C; pH: 7.3-7.4). 44 CBF was continuously monitored at the site of superfusion with a laser-Doppler probe (Vasamedic, St. Paul, MN) positioned stereotaxically on the neocortical surface and connected to a computerized data acquisition system. CBF values were expressed as percent increase relative to the resting level. Resting CBF is reported as arbitrary laser-Doppler perfusion units. Zero values for CBF were obtained after the heart was stopped by an overdose of isoflurane at the end of the experiment.
Experimental Protocol for CBF Experiments
CBF recordings were started after arterial pressure and blood gases were in a steady state. CBF responses to whisker stimulation were recorded while gently stroking the whiskers with a cotton-tipped applicator for 60 seconds. All pharmacological agents were dissolved in a modified Ringer solution. To test endothelium-dependent responses, the endothelial NO-dependent vasodilator acetylcholine (10 µmol/L, Sigma), the Ca 2+ ionophore A23187 (3 µmol/L; Sigma), or bradykinin (50 µmol/L; Sigma) was topically superfused for 3 to 5 minutes, and the evoked CBF increases recorded. To test smooth muscle reactivity, CBF response to adenosine (400 µmol/L; Sigma) or the NO donor S-nitroso-N-acetyl-dl-penicillamine (SNAP; 50 µmol/L; Sigma) was examined. 24, 25, 42 The increase in CBF produced by hypercapnia was tested by introducing 5% CO 2 in the ventilator to increase arterial pCO 2 ≤50 to 60 mm Hg. Once a stable increase in CBF was obtained for 3 to 5 minutes, pCO 2 was returned to normocapnia.
Measurement of Aβ
Aβ was measured using an ELISA-based assay, as described previously. 23, 24, 26 Briefly, the left hemispheres from the mice used for CBF studies were sonicated in 1% SDS with protease inhibitors and centrifuged. The supernatant contained SDS-soluble Aβ peptides. The pellet was sonicated in 70% formic acid and centrifuged as above. The formic acid extract was neutralized by a 1:20 dilution into 1 mol/L Tris phosphate buffer (pH 8.0). Aβ 1-40 and Aβ 1-42 concentrations (picomolar) were determined in supernatant (SDS-soluble) and in the formic acid extract of the pellet (SDS-insoluble) using the BAN-50/ BA-27 and BAN-50/BC005 sandwich ELISA assay.
Statistics
Sample size was determined by power analysis based on previously published works published by our laboratory on CBF regulation. Animals were randomly assigned to treatment or control group, and analysis was performed in a blinded fashion. Group difference was analyzed using Student t test (paired or unpaired) or ANOVA with Tukey test, as appropriate. Data are expressed as mean±SEM, and statistical difference was considered significant at P<0.05. 
Results
Brain PVM Depletion Ameliorates the Neurovascular Dysfunction Induced by Aβ
PVM, identified by CD206 immunochemistry, their perivascular location, and their ability to phagocytize dextran were observed in close apposition to somatosensory cortex blood vessels (Figure 1; Online Figure I ). In particular, PVM were juxtaposed to penetrating arterioles identified by the smooth muscle cell marker α-actin (Online Figure I) , attesting to their association with cerebral resistance vessels. PVM also expressed CD36 (Online Figure II) , the innate immunity receptor involved in the cerebrovascular effects of Aβ. 25, 26 Consistent with previous observations, 34 PVM were not observed in vessels smaller than 10 µm (precapillary arterioles and capillaries) because of the fusion of the glial and vascular basement membranes and obliteration of the perivascular space. 29 To deplete brain PVM, we used intracerebroventricular injection of liposome-encapsulated clodronate and assessed the extent of the depletion 5 days later, when the effect is most pronounced and stable. 34, 38 Clodronate, but not control liposomes, deplete PVM and meningeal macrophages in the somatosensory cortex (>80%). In agreement with previous observations in adult mice, 34 clodronate did not deplete microglia, smooth muscle cells, astrocytes, or endothelium (Figure 1 As reported before, [23] [24] [25] [26] 42 the CBF response to neocortical application of the smooth muscle relaxant adenosine or to hypercapnia, a potent cerebrovasodilatatory stimulus, 45, 46 was not affected ( Figure 2D ; Online Figure IVD ; P>0.05). However, we cannot rule out that a reduction would be observed with a milder hypercapnic challenge producing smaller CBF increases. PVM depletion by clodronate did not alter CBF responses but prevented in full the Aβ-induced attenuation in functional hyperemia, endothelium-dependent responses, and response to SNAP (Figure 2A Figure 2E ).
To provide further evidence that PVM participate in the neurovascular effects of Aβ, we used 3-to 4-month-old Tg2576 mice. 23, 25, 42 At this age, Tg2576 mice have elevated levels of brain Aβ but do not exhibit amyloid pathology (amyloid plaques and cerebral amyloid angiopathy). [23] [24] [25] [26] 42 The number of PVM did not differ between Tg2576 mice and WT littermates ( Figure  1E ), but the intensity of the CD36 immunolabel seemed greater in CD206 + PVM of Tg2576 mice (Online Figure IIB) , as reported. 25, 26 Clodronate depleted PVM in Tg2576 mice as effectively as in WT mice (Figure 1 
Deletion of CD36 or Nox2 in PVM Ameliorates the Neurovascular Dysfunction
We used CD36 −/− or Nox2 −/− BM chimeras to replace PVM with PVM lacking CD36 or Nox2 in WT and Tg2576 mice. After lethal irradiation, PVM are eliminated and slowly replaced with BM-derived macrophages, but microglia and other resident brain cells are not affected, at least in young WT and APP mice. 34, 47 This approach has been previously used for gene targeting in PVM. 34, 47 Because immune cell trafficking may be altered in APP-expressing mice, 36, 47, 48 we first investigated whether the repopulation of the perivascular space by PVM after BM transplant was comparable in WT and Tg2576 mice. GFP + BM was transplanted in WT and Tg2576 mice, and 2 months later, perivascular GFP + cells were examined in both groups. We found that the number of PVM and their perivascular distribution did not differ between WT and Tg2576 mice (Online Figure V) . Furthermore, to investigate whether PVM repopulation is altered by lack of CD36 or Nox2 in macrophages, we quantified PVM in tg2676 mice transplanted with CD36 −/− or Nox2 −/− BM, and there were no differences in number and distribution of PVM ( Figure 4A through 4E) .
Next, we studied the cerebrovascular dysfunction induced by Aβ in BM chimeras. Functional hyperemia, endotheliumdependent CBF responses, and responses to adenosine, SNAP, or hypercapnia in WT mice receiving WT BM (WT→WT) were identical to those observed in naive WT mice ( 
PVM Depletion Ameliorates the Neurovascular Dysfunction Induced by Circulating Aβ
Circulating and brain Aβ both have a role in neurovascular dysfunction, an effect mediated by ROS. 25, 49 Circulating Aβ is thought to cross the blood-brain barrier by engaging the receptor for advanced glycation end products. 50 Therefore, we sought to determine whether PVM also contribute to the neurovascular effects of circulating Aβ. To this end, first we sought to establish whether blood-borne Aβ enters the perivascular space and reaches PVM. Intracarotid administration of cyanine 5-labeled Aβ 1-40 , at a concentration and infusion rate that produce a steady-state increase in plasma Aβ comparable to that of Tg2576 mice, 25, 49 was able to cross the vascular wall, enter the perivascular space, and reach PVM (Figure 7A and 7B; Online Figure VIII) . Clodronate depleted PVM without affecting cyanine 5-labeled Aβ 1-40 ( Figure 7C and 7D) . As previously reported, 25, 49 Aβ 1-40 infusion resulted in attenuation of the CBF increase produced by whisker stimulation and by endothelium-dependent vasodilators in the somatosensory cortex ipsilateral to the infusion, whereas endothelium-independent responses were not affected ( Figure 7E ). PVM depletion prevented in full the neurovascular dysfunction induced by circulating Aβ , an effect associated with suppression of vascular oxidative stress ( Figure 7E ).
Discussion
Several studies have shown that Aβ leads to vascular dysfunction through oxidative stress, 16, 17, 20 but the effector cells exposed to Aβ and responsible for the ROS production were not identified. Because brain PVM can produce large amounts of ROS 34 and are located in the perivascular space, a major site of brain Aβ trafficking and accumulation, 31, 33 we sought to determine whether PVM are involved in the neurovascular effects of the peptide. We found that selective depletion of PVM abrogates the vascular oxidative stress and neurovascular dysfunction induced by Aβ, either applied directly to the neocortex of WT mice or produced endogenously in Tg2576 mice. The effect could not be attributed to depletion of microglia, to nonspecific alterations in vascular structure and reactivity resulting in vasoparalysis, or to reductions in brain Aβ in Tg2576 mice. Elevated levels of circulating Aβ have been implicated in vascular alterations in AD and other dementias [51] [52] [53] [54] and lead to cerebrovascular disturbances in animal models. 49 Therefore, we asked whether PVM also contribute to the deleterious neurovascular effects of circulating Aβ. We found that intravascular Aβ crosses the vascular wall, enters the perivascular space, reaches PVM, induces ROS production, and alters neurovascular function. These novel observations establish PVM as the main source of the vascular ROS responsible for the CBF alterations induced by parenchymal and plasma Aβ.
Next, we sought to establish whether CD36 and Nox2 in PVM are required for the deleterious cerebrovascular effects of Aβ. To this end, we used BM chimeras in which CD36 or Nox2 was deleted in PVM by transplantation of CD36-or Nox2-deficient BM. First, we verified that the extent of PVM replacement by blood-borne myeloid cells was comparable between the 2 mouse lines and was not altered by lack of CD36 or Nox2. Then, we tested the cerebrovascular effects of Aβ in the chimeras. The BM transplant procedure did not alter −/− or Nox2 −/− bone marrow (BM) in Tg2576 mice on perivascular macrophage (PVM) number and reactive oxygen species (ROS) production. Vessels are labeled with DiO (DiOC18(3) (3,3′-dioctadecyloxacarbocyanine perchlorate; red), ROS production is detected with (dihydroethidium, blue), and PVM are labeled with dextran (green). In wild-type (WT) mice transplanted with WT BM (WT→WT), PVM have numbers and distribution comparable to those of naive WT mice (A). Similarly, Tg2576 mice transplanted with WT BM (WT→Tg) exhibited number and distribution similar to those of naive Tg2576 mice (B). However, ROS production in PVM was observed in WT→Tg mice (DHE inset in B). Transplant of CD36 −/− (CD36→Tg) or Nox2 −/− (Nox2→Tg) BM in Tg2576 mice does not alter PVM number or distribution but suppresses PVM ROS production (DHE insets in C and D). Quantification of the numbers of PVM in the BM chimeras studied (E). Quantification of cerebrovascular ROS in the BM chimeras showing that ROS production is suppressed in CD36→Tg and Nox2→Tg mice (F). RFU indicates relative fluorescent units; *P<0.05 from WT→WT, CD36→Tg, or Nox2→Tg; ANOVA and Tukey test; n=5 per group.
CBF regulation in WT mice or the suppression of neurovascular responses in Tg2576 mice. However, transplantation of CD36-or Nox2-deficient BM abrogated the cerebrovascular dysfunction and vascular oxidative stress in WT mice exposed to exogenous Aβ or in Tg2576 mice. Furthermore, WT BM was able to re-establish Aβ-induced vascular dysfunction in CD36-deficient mice, suggesting that the CD36-signaling pathway in PVM is absolutely necessary for the harmful Although cerebral endothelial cells in culture have the potential to produce ROS in response to Aβ via CD36 42 , depletion of PVM completely abrogates vascular oxidative stress and neurovascular dysfunction, suggesting an essential role of PVM in the neurovascular effects of Aβ in vivo. Therefore, previous results in which Aβ vasoactivity was not observed in CD36-null mice 25 have to be attributed to lack of CD36 in PVM and not endothelial cells. This conclusion is also supported by our finding that WT BM transplant in CD36 −/− mice, in which endothelial cells lack CD36, re-establishes the ROS-dependent neurovascular dysfunction induced by Aβ. Therefore, WT PVM are able to drive the neurovascular dysfunction even if endothelial cells lack CD36. Aβ has also been reported to increase ROS in isolated cerebral blood vessels. 25, 55 However, these vascular preparations are likely to also include PVM, which remain attached to the outer vessel wall during the isolation procedure.
There has been an increasing appreciation for the role of PVM in the brain's own innate immunity system. 35, 36 PVM, a unique population of brain myeloid cells distinct from microglia, have been implicated in hypothalamic-adrenal axis and neurohumoral activation in the setting of myocardial infarction, emotional stress, or systemic inflammation. [56] [57] [58] PVM may also have a role in neuroimmune trafficking in brain infections 38, 58 and in the structural and functional cerebrovascular alterations of hypertension, 34, 59 as well as in tumor angiogenesis and cerebrovascular repair. 60 In models of cerebral amyloidosis, PVM depletion reduces Aβ accumulation in cerebral blood vessels. 61 The present results expand our understanding of the pathobiology of these cells in AD by revealing a key role of PVM in Aβ-induced neurovascular dysfunction.
The perivascular compartment and associated innate immune cells have recently attracted much attention in the mechanisms of AD.
33,62 The brain's perivascular space is a major conduit for clearance of toxic molecules from the brain, including Aβ. 33, 63 In AD, tortuous perivascular spaces may impede Aβ clearance from the brain and promote the harmful interaction between Aβ and cerebral blood vessels, as well as cerebral amyloid angiopathy. 30, 31, 64 Our results provide the first demonstration that PVM are the cells in the perivascular space driving the neurovascular dysfunction induced by Aβ. On the other hand, increasing evidence suggests a role of innate immunity cells and receptors in AD pathogenesis. 62 Although microglial cells, resident brain immune cells, may degrade Aβ and shield the brain from the deleterious effects of amyloid, 62, 65 innate immunity receptors, including CR1 (complement receptor type 1), TREM2 (triggering receptor expressed on myeloid cells 2), CD33 (cluster of differentiation 33), and CD36, among others, have been linked to increased AD susceptibility in genome-wide association studies. 22, 62 However, it remained unclear how innate immunity exerts its harmful effects in AD. 36 Our findings identify PVM as critical cells initiating Aβ-induced neurovascular dysfunction and suggest a new mechanism by which innate immune cells in the perivascular space may contribute to AD.
A limitation of the present study is that, by using presymptomatic Tg2576 mice, we could not assess the impact of PVM on the cognitive deficits associated with Aβ accumulation. This is for the following reasons: considering that the effect of clodronate is limited to a few weeks, 38 we could not determine whether PVM depletion protects Tg2576 mice from cognitive deficits, which develop during several months. 24, 26, 37 We also explored the possibility of using BM chimeras to delete Nox2 and CD36 in PVM. However, this approach proved not to be feasible because, as the Tg2576 BM chimeras age, the brain parenchyma is infiltrated by BM-derived cells with the morphological characteristics of microglia (Park and Iadecola, unpublished data, 2017). 47 Figure 7. Circulating amyloid-β peptide (Aβ 1-40 ) reaches perivascular macrophage (PVM) and mediates oxidative stress and neurovascular dysfunction. In wild-type (WT) mice treated with PBS, cyanine 5 (Cy5)-labeled Aβ 1-40 infused into the carotid artery (Cy5-Aβ 1-40 ; 1 µmol/L, 150 µL/h; blue) colocalizes with dextran-labeled PVM (green) surrounding cerebral blood vessels labeled with DiO (DiOC18(3) (3,3′-dioctadecyloxacarbocyanine perchlorate; red) and resulting in the cyan color in the merged image (A). Orthogonal projections illustrating colocalization of dextran-labeled PVM (green) and Cy5-labeled Aβ (blue) around blood vessels (red; A). Cy5-labeled Aβ is colocalized with >80% of dextran-positive PVM (B). In mice treated with clodronate, the signal from Cy5-labeled Aβ 1-40 is still present in the brain and not different from PBS-treated mice (C) but is no longer associated with PVM, which are depleted (Online Figure VIII) . Reactive oxygen species (ROS) are increased in PVM of mice receiving the intracoronary infusion of Aβ 1-40 (icAβ ), which is suppressed by clodronate treatment (D). icAβ attenuates the increase in cerebral blood flow (CBF) induced by whisker stimulation or acetylcholine, an effect reversed by clodronate (E). Resting CBF or the CBF response to adenosine is not affected by icAβ (E). LDU indicates arbitrary laser-Doppler perfusion units; and RFU, relative fluorescence units; *P<0.05 from vehicle, ANOVA and Tukey test; n=5 to 6 per group. Therefore, the specific contribution of PVM replacement could not be reliably assessed under these conditions. These limitations notwithstanding, considering the well-established link between neurovascular dysfunction and cognitive impairment in this mouse model, 24, 26 it is reasonable to postulate that PVM depletion may result in improved cognition. However, this assumption needs to be verified experimentally. Future studies using more suitable methods to selectively target PVM in older APP mice could assess the role of PVM on cognitive dysfunction, as well as in the phosphorylation of tau, a major pathogenic factor in AD, which is influenced by endothelial NO. 66 In conclusion, we have demonstrated that PVM are essential for the neurovascular dysfunction induced by Aβ in 3 separate mouse models. PVM exert their harmful effects through the Aβ receptor CD36 and the ROS-producing enzyme Nox2. PVM are also needed for the neurovascular dysfunction induced by circulating Aβ, an effect mediated by Aβ entering the perivascular space and reaching PVM to induce vascular oxidative stress. The findings identify PVM as the missing link between Aβ and neurovascular dysfunction and unveil a new mechanism by which innate immune cells and receptors, long thought to play a role in the disease, contribute to the pathobiology of AD. Therefore, manipulating PVM could be a promising therapeutic strategy to stave off Aβ-induced brain dysfunction and damage.
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